the aid library

Download

View PDF

Antidepressants (Tricyclic Antidepressants and Selective Serotonin Reuptake Inhibitors) in treatment of adults with depression

World Health Organization WHO (2012) C_WHO

Q 1: Are antidepressants (Tricyclic Antidepressants (TCA) and Selective Serotonin Reuptake Inhibitors ... more

Download

View PDF

CH 4: Antidepressants among adolescents with moderate-severe depressive disorder for whom psychosocial interventions have proven ineffective

World Health Organization (2015) C_WHO

(2015) Scoping question: Are antidepressants (specifically, tricyclic antidepressants and selective serotonin reuptake ... more

Download

View PDF

Selective mutism

B. Oerbeck; K. Manassis; K. R. Overgaard; H. Kristensen IACAPAP (2016) C2

Anxiety disorders Chapter F.5

Download

View PDF

Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults

A. Locke, N. Kirst, C.G. Shultz American Academy of Family Physicians (2015) C2

Download

View PDF

Duration of antidepressant treatment

World Health Organization WHO (2012) C_WHO

Q 2: How long should treatment with antidepressants continue in adults with depressive episode/disorder?

External Link

Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care

B. Bandelow, L. Sher, R. Bunevicius, et al. (2012) C2

International Journal of Psychiatry in Clinical Practice, 2012; 16: 77–84

Download

View PDF

Practice Guidelines for Treating Gambling-Related Problems

Korn, D.A. and H.J. Shaffer (2004) CC

An Evidence-Based Treatment Guide for Clinicians

Download

View PDF

Panic disorder: When fear overwhelmes

National Institute of Mental Health NIH NIMH (2016) C1

Do you sometimes have sudden attacks of anxiety and overwhelming fear that last for several minutes? Maybe your heart pounds, you sweat, and you feel like you can’t breathe or think. Do these attacks occur at unpredictable times with no obvious trigger, causing you to worry about the possibi ... more

Download

View PDF

Management of Dry Eye Disease in India. Quick Reference Guide (Draft)

National Health Mission; Ministry of Health & Social Welfare India (2016) C1

Standard Treatment Guideline

Download

View PDF

Organizing and delivering services for child and adolescent mental health

C. Servili IACAPAP (2012) C2

Miscellaneous Chapter J.5

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Hepatology. A Clinical Textbook

Stefan Mauss, et al. Flying Publisher, Boehringer Ingelheim (2015)

Download

View PDF

WHO mhGAP Guideline update
recommended

WHO WHO (2015) C_WHO

Update of the Mental Health Gap Action Programme (mhGAP) Guideline for Mental, Neurological and Substance use Disorders May 2015

Download

View PDF

Principles in using psychotropic medication in children and adolescents

B. Vitiello IACAPAP (2012) C2

Introduction Chapter A.7

Download

View PDF

Trastorno Obsesivo-Compulsivo en el niño y el Adolescente

P. Gomes de Alvarenga; R. S. Mastrorosa, M. Conceição do Rosário IACAPAP (2018) C2

Trastornos de ansiedad Capítulo F.3 Editores: Laura Revert, Matías Irarrázaval & Andres Martin Traducción: Régis Villegas, Paula Placencia, José Ángel Alda & Paula Cox

Download

View PDF

Out of the Shadows. Making Mental Health a Global Development Policy
recommended

Seth Mnookin World Bank Group, and World Health Organization WHO (2016) C_WHO

Mental disorders impose an enormous burden on society, accounting for almost one in three years lived with disability globally. •In addition to their health impact, mental disorders cause a significant economic burden due to lost economic output and the link between mental disorders and costly, po ... more

Download

View PDF

Group Interpersonal Therapy (IPT) For Depression

World Health Organization WHO (2016) C_WHO

WHO recommends interpersonal therapy (IPT) as a possible first line treatment for depression. With this new manual, the World Health Organization (WHO) gives guidance on the use of interpersonal therapy (IPT) using a 8 session group protocol. The manual - which is part of WHO’s mhGAP programme - d ... more